Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.

Jan A. Burger; Klaus Okkenhaug

doi:10.1038/nrclinonc.2014.42

Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.

Jan A. Burger, Klaus Okkenhaug

Leukemia

Research output: Contribution to journal › Comment/debate › peer-review

47 Scopus citations

Original language	English (US)
Pages (from-to)	184-186
Number of pages	3
Journal	Nature reviews. Clinical oncology
Volume	11
Issue number	4
DOIs	https://doi.org/10.1038/nrclinonc.2014.42
State	Published - Apr 2014

ASJC Scopus subject areas

Oncology

Access to Document

10.1038/nrclinonc.2014.42

Cite this

@article{37fb148cf93c44cfa6762eab52a6940f,

title = "Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.",

author = "Burger, {Jan A.} and Klaus Okkenhaug",

year = "2014",

month = apr,

doi = "10.1038/nrclinonc.2014.42",

language = "English (US)",

volume = "11",

pages = "184--186",

journal = "Nature reviews. Clinical oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Haematological cancer

T2 - idelalisib-targeting PI3Kδ in patients with B-cell malignancies.

AU - Burger, Jan A.

AU - Okkenhaug, Klaus

PY - 2014/4

Y1 - 2014/4

UR - http://www.scopus.com/inward/record.url?scp=84908130105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908130105&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2014.42

DO - 10.1038/nrclinonc.2014.42

M3 - Comment/debate

C2 - 24642682

AN - SCOPUS:84908130105

SN - 1759-4774

VL - 11

SP - 184

EP - 186

JO - Nature reviews. Clinical oncology

JF - Nature reviews. Clinical oncology

IS - 4

ER -

Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this